Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Based on historical patterns, NGNE typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-12 | +$0.65 (+2.10%) | $1.52 (4.90%) | +$1.08 (+3.42%) | $3.47 (11.00%) |
| 2026-03-24 | +$1.54 (+7.95%) | $2.69 (13.89%) | +$1.13 (+5.41%) | $2.54 (12.15%) |
| 2025-11-13 | -$4.59 (-14.77%) | $4.00 (12.87%) | -$3.72 (-14.04%) | $5.21 (19.66%) |
| 2025-08-11 | -$0.87 (-4.10%) | $2.23 (10.51%) | -$1.13 (-5.55%) | $2.17 (10.66%) |
| 2025-05-09 | -$0.27 (-1.80%) | $2.31 (15.40%) | +$2.97 (+20.16%) | $3.82 (25.93%) |
| 2025-03-24 | -$0.25 (-1.76%) | $0.99 (6.97%) | +$0.24 (+1.72%) | $1.47 (10.53%) |
| 2024-11-18 | -$14.70 (-42.58%) | $4.85 (14.05%) | -$2.59 (-13.07%) | $3.98 (20.08%) |
| 2024-08-09 | -$0.96 (-2.63%) | $2.24 (6.13%) | -$0.90 (-2.53%) | $3.51 (9.86%) |
| Avg Abs Move | 9.71% | 10.59% | 8.24% | 14.99% |
Neurogene's post-earnings price behavior has been highly volatile and directionally mixed, with an average absolute Day 0 move of 9.71% and Day +1 move of 8.24%. The stock has experienced dramatic swings in both directions, with the most extreme example being the November 2024 report, which saw a 42.58% decline on Day 0 followed by an additional 13.07% drop on Day +1.
More recently, the pattern has moderated somewhat but remains unpredictable. The March 2026 report produced a 7.95% gain on Day 0 and a 5.41% gain on Day +1, while the May 2026 report saw more modest moves of 2.10% and 3.42% respectively. The wide Day 1 range averaging 14.99% indicates that the stock frequently experiences significant intraday volatility as investors digest the results and management commentary.
Investors should prepare for substantial price movement in either direction, with historical data suggesting that double-digit percentage swings are not uncommon for NGNE around earnings releases.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 14) |
| Expected Move | $2.55 (7.17%) |
| Expected Range | $33.03 to $38.13 |
| Implied Volatility | 106.67% |
The options market is pricing in an expected move of 7.17% for the upcoming earnings release, which is below the stock's average historical Day 0 move of 9.71% and Day +1 move of 8.24%. This suggests that options traders may be underestimating the potential volatility, particularly given NGNE's history of dramatic post-earnings swings exceeding 10% in several recent quarters.
Part 3: What Analysts Are Saying
Analyst sentiment on Neurogene remains overwhelmingly bullish, with the stock carrying an average recommendation of 4.82 out of 5.0, indicating strong buy conviction. The current consensus includes 10 strong buy ratings, 0 moderate buys, 1 hold, and no sell ratings across 11 analysts covering the stock. This represents unchanged sentiment compared to one month ago, suggesting analysts have maintained their conviction despite the recent earnings miss.
The average price target of $80.25 implies substantial upside of approximately 125% from the current price of $35.69. Price targets range widely from a low of $46.00 to a high of $180.00, reflecting differing views on the company's pipeline value and probability of clinical success. The wide dispersion in targets is typical for clinical-stage biotechnology companies, where outcomes are binary and highly dependent on trial results.
The stability in analyst sentiment heading into this report suggests that the Street remains confident in Neurogene's long-term prospects despite near-term losses widening. The lack of any downgrades following the March 2026 earnings miss indicates that analysts view the company's increased spending as an investment in value-creating clinical development rather than a sign of operational challenges.
Part 4: Technical Picture
Neurogene is entering earnings with strong technical momentum, as reflected in the Barchart Technical Opinion showing a 96% Buy signal, up from 88% last week and down slightly from 100% last month. The stock is trading at $35.69, positioned above all major moving averages, including the 5-day ($34.91), 10-day ($34.25), 20-day ($35.69), 50-day ($32.94), 100-day ($29.02), and 200-day ($25.32). This alignment indicates a healthy uptrend across all timeframes.
Timeframe Analysis:
- Short-term (75% Buy): Strong buy signal indicates solid near-term momentum heading into the earnings release, though not at maximum bullishness
- Medium-term (100% Buy): Maximum buy signal suggests robust intermediate-term trend strength and positive positioning
- Long-term (100% Buy): Maximum buy signal reflects strong conviction in the longer-term uptrend, with the stock well above its 200-day moving average
The trend is characterized as Strong and Strengthening, indicating that momentum has been building recently and the technical environment is supportive heading into the earnings event.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $34.91 | 50-Day MA | $32.94 |
| 10-Day MA | $34.25 | 100-Day MA | $29.02 |
| 20-Day MA | $35.69 | 200-Day MA | $25.32 |
The stock's position above all key moving averages, combined with the strengthening technical opinion, suggests a supportive setup for earnings. The 200-day moving average at $25.32 provides a significant cushion below current levels, indicating the stock has built substantial technical support during its uptrend. However, with the stock trading on its 20-day moving average, there is limited near-term cushion, meaning a disappointing report could quickly test support at the 50-day moving average around $32.94. The strong technical backdrop may help contain downside volatility, but given NGNE's history of dramatic post-earnings moves, traders should be prepared for the stock to break out of its recent range in either direction regardless of the current positive technical setup.